A Phase 1 Dose-Escalation Study of Intraperitoneal Cisplatin, Intravenous/Intraperitoneal Paclitaxel, Bevacizumab, and Olaparib for Newly Diagnosed Ovarian Cancer

OBJECTIVE: We assessed the safety and maximum tolerated dose (MTD) of the poly ADP-ribose polymerase (PARP) inhibitor olaparib with intravenous (IV)/intraperitoneal (IP) cisplatin/paclitaxel and IV bevacizumab, followed by olaparib and bevacizumab maintenance, in patients with newly diagnosed ovaria...

Full description

Saved in:
Bibliographic Details
Published in:Gynecol Oncol
Main Authors: Cadoo, Karen A., Grisham, Rachel N., O’Cearbhaill, Roisin E., Boucicaut, Nicole N., Henson, Melissa, Iasonos, Alexia, Zhou, Qin, Sarasohn, Debra M., Gallagher, Jacqueline, Kravetz, Sara, Zamarin, Dmitriy, Makker, Vicky, Sabbatini, Paul J., Tew, William P., Aghajanian, Carol, Konner, Jason A.
Format: Artigo
Language:Inglês
Published: 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7127949/
https://ncbi.nlm.nih.gov/pubmed/31959492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.01.018
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items